Novartis: Bryan Garnier raises target price
(CercleFinance.com) - Bryan Garnier has reinstated its "buy" rating on Novartis and has upped its fair value for the share from 94 Swiss francs to 96 Swiss francs, after the group raised its estimates after unveiling its annual results.
The broker highlights better-than-expected published figures, creating a higher comparison basis for future growth, as well as Novartis' 2018 targets, which are deemed "reassuring".
Bryan Garnier also points out "general comments made by new CEO focusing a lot on future margin growth driven by innovation and productivity."
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker highlights better-than-expected published figures, creating a higher comparison basis for future growth, as well as Novartis' 2018 targets, which are deemed "reassuring".
Bryan Garnier also points out "general comments made by new CEO focusing a lot on future margin growth driven by innovation and productivity."
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.